Nicox Provides Fourth Quarter 2022 Financial Highlights
Press ReleaseNicox Provides Fourth Quarter 2022 Financial HighlightsNet revenue €1.0 million for fourth quarter 2022, and €3.3 million for the...
Clinical Trial
BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
Dr Nicco will oversee the development of pipeline across BioSenic’s cell therapy and autoimmune disease platform and will be responsible...
Junshi Biosciences Announces Acceptance of NDA for VV116 in China
SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology...
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of...
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of...
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of...
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S....
Shockwave Medical Announces Agreement to Acquire Neovasc
Neovasc’s Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical Announces Preliminary Fourth Quarter and...
Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
-Initiation of Phase 2b trial follows clearance from the US Food and Drug Administration (FDA) and Spanish Agency for Medicines...
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) ---- Median percent change in LDL-C of...
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare...
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal...
Oncotelic Announces the launch of PDAO token
- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics,...
Shockwave Medical to Acquire Neovasc
VANCOUVER, BC, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN), a...